Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature

Authors

DOI:

https://doi.org/10.35434/rcmhnaaa.2021.141.821

Keywords:

COVID-19, hydroxychloroquine, tocilizumab, anakinra, baricitinib, antirheumatic agents

Abstract

We are currently in a global pandemic caused by the coronavirus 2019 or COVID-19, presenting different challenges for the health system due to the fact that there is still no vaccine or a treatment that has proven its effectiveness in its entirety, being the management current preventive and supportive. Therefore, this review will study the most prominent antirheumatic drugs that have a probable pharmacological effect, such as hydroxychloroquine, tocilizumab, anakinra and baricitinib, against COVID-19. It is expected that they will provide support for future treatments. and research on the disease.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biographies

Rosa Alejandra Salas-Bolaños, Bachiller de Medicina Humana

  1. Facultad de Medicina Humana, Universidad Privada Antenor Orrego, Trujillo, Perú

David Ezequiel Sevilla-Rodriguez, Magister en Medicina

  1. Facultad de Medicina Humana, Universidad Privada Antenor Orrego, Trujillo, Perú

Abel Salvador Arroyo-Sánchez, Doctor en Salud Pública

  1. Facultad de Medicina Humana, Universidad Privada Antenor Orrego, Trujillo, Perú
Rev. Cuerpo Med. HNAAA

Additional Files

Published

2021-04-27

How to Cite

1.
Salas-Bolaños RA, Sevilla-Rodriguez DE, Arroyo-Sánchez AS. Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature. Rev. Cuerpo Med. HNAAA [Internet]. 2021 Apr. 27 [cited 2024 Nov. 23];14(1):52-63. Available from: http://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/821

Issue

Vol. 14 No. 1 (2021): January - March

Section

Review Article
Crossref
Scopus
Google Scholar
Europe PMC